For the Inventor, By the Inventor

Enter assignee name

Kvistgaard, Denmark

Bavarian Nordic A/s

USPTO Granted Patents = 132

CIPO Patents = 12

EPO Patents = 39

Trademarks = 21

Forward Citations = 876

Loading Chart...

Loading Chart...

80 inventors (with patents filed for the assignee):

Paul Michael Howley (45 out of 49 patents)

Paul Chaplin (39 out of 39 patents)

Robin Steigerwald (26 out of 26 patents)

4. Sonja Leyrer (26 out of 27 patents)

5. Eva Felder (24 out of 24 patents)

6. Hubertus Hochrein (16 out of 16 patents)

7. Christine Meisinger-Henschel (16 out of 16 patents)

8. Karl Heller (13 out of 13 patents)

9. Ulrike Dirmeier (10 out of 10 patents)

10. Ingmar Rathe (10 out of 10 patents)

11. Markus Kalla (9 out of 9 patents)

12. Ariane Volkmann (9 out of 9 patents)

13. Jürgen Hausmann (8 out of 8 patents)

14. Sara Post Hansen (8 out of 8 patents)

15. Henning Lauterbach (7 out of 7 patents)

Core Competencies:

Recombinant Vaccinia Virus

Poxvirus Compositions

Filovirus Immunogens

Cancer Combination Therapy

Transgene Stability

HIV Antigen Vectors

Intratumoral Administration

Protective Immunity

T-Cell Responses

Vaccine Immune Responses

Modified Vaccinia Ankara

Hepatitis B Virus

132 patents: Sort by Forward Citations

1. 12390515 - Therapy for treating cancer with an intratumoral or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L (2025-08-19),

2. 12150988 - Storage improved poxvirus compositions (2024-11-26),

3. 11918639 - Methods and compositions for inducing protective immunity against filovirus infection (2024-03-05),

4. 11753652 - Cassette encoding a FPV/brachyury fusion protein (2023-09-12),

5. 11723970 - Poxvirus vectors encoding HIV antigens, and methods of use thereof (2023-08-15),

6. 11723964 - Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA (2023-08-15),

7. 11654189 - Compositions and methods for enhancing the stability of transgenes in poxviruses (2023-05-23),

8. 11571471 - Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine (2023-02-07),

9. 11338030 - Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens (2022-05-24),

10. 11273211 - Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody (2022-03-15),

11. 11229693 - Poxvirus vectors encoding HIV antigens, and methods of use thereof (2022-01-25),

12. 11225673 - Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity (2022-01-18),

13. 11173204 - MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen (2021-11-16),

14. 11173201 - Methods and compositions for inducing protective immunity against filovirus infection (2021-11-16),

15. 11103570 - Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine (2021-08-31),

Bavarian Nordic A/S is a biotechnology company specializing in the research, development, manufacture, and commercialization of vaccines. The company's primary focus is on the development of vaccines for infectious diseases, including cancer immunotherapies and treatments for Ebola and HIV. With a strong commitment to innovation and collaboration, Bavarian Nordic aims to improve global health by providing safe and effective vaccines to protect against various diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

132 Patents

#1 in Kvistgaard

#31 in Denmark

#5,922 in the World

Kvistgaard, Denmark

Bavarian Nordic A/s

Forward Citations = 876

80 inventors:

Paul Michael Howley (45 out of 49 patents)

Paul Chaplin (39 out of 39 patents)

Robin Steigerwald (26 out of 26 patents)

4. Sonja Leyrer (26 out of 27 patents)

5. Eva Felder (24 out of 24 patents)

Please report any incorrect information to support@idiyas.com

Loading…